Bacteriology
Point-of-care testing for CXCL13 in Lyme neuroborreliosis

https://doi.org/10.1016/j.diagmicrobio.2018.02.013Get rights and content

Highlights

  • Cerebrospinal fluid CXCL13 is a marker for Lyme neuroborreliosis.

  • A new CXCL13 lateral flow immunoassay performs excellently compared with an ELISA.

  • The CXCL13 lateral flow immunoassay is suitable for point-of-care diagnostics.

Abstract

Cerebrospinal fluid chemokine (C-X-C motif) ligand 13 (CXCL13) is a marker for Lyme neuroborreliosis (LNB). CXCL13 lateral flow immunoassay (LFA) was compared with CXCL13 ELISA. CXCL13 LFA results correlated strongly with CXCL13 ELISA results. CXCL13 LFA is a rapid and easy-to-perform test, which is suitable for routine point-of-care diagnostics of suspected LNB patients.

Section snippets

Funding

This work was supported by a grant from the Jane and Aatos Erkko Foundation. This work was financially supported by Reagena by providing the CXCL13 LFA tests.

Competing interests

J.H. is a part-time consultant for Reagena.

Authors' contributions

JH designed the study, performed chemokine analyses, analyzed the data, and drafted the manuscript. AP performed chemokine analyses, analyzed the data, and helped to draft the manuscript. JO analyzed the data and helped to draft the manuscript. All authors read and approved the final manuscript.

Acknowledgments

Tuula Rantasalo is acknowledged for performing chemokine analyses.

References (14)

  • G. Stanek et al.

    Lyme borreliosis

    Lancet

    (2012)
  • D. Bremell et al.

    Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection

    BMC Neurol

    (2013)
  • S. Hammers-Berggren et al.

    Borrelia burgdorferi–specific intrathecal antibody production in neuroborreliosis: a follow-up study

    Neurology

    (1993)
  • J. Hytönen et al.

    CXCL13 and neopterin concentrations in cerebrospinal fluid of patients with Lyme neuroborreliosis and other diseases that cause neuroinflammation

    J Neuroinflammation

    (2014)
  • F.C. Knudtzen et al.

    Characteristics and clinical outcome of Lyme neuroborreliosis in a high endemic area, 1995–2014: a retrospective cohort study in Denmark

    Clin Infect Dis

    (2017)
  • U. Koedel et al.

    Lyme neuroborreliosis—epidemiology, diagnosis and management

    Nat Rev Neurol

    (2015)
  • U. Koedel et al.

    Lyme neuroborreliosis

    Curr Opin Infect Dis

    (2017)
There are more references available in the full text version of this article.

Cited by (13)

  • CXCL13 in patients with facial palsy caused by varicella zoster virus and Borrelia burgdorferi: a comparative study

    2020, Diagnostic Microbiology and Infectious Disease
    Citation Excerpt :

    As such, the added benefit of CXCL13 would be to avoid unnecessary antibiotic prescriptions and move focus to potential differential diagnoses. In a newly published study by Pietikäinen et al. (Pietikainen et al., 2018), the authors advocate for a new CXCL13 lateral flow assay, suitable for point-of-care testing. Such an assay could potentially widen the indication for CXCL13 testing, and have an impact on clinical practice.

  • Unconventional diagnostic tests for Lyme borreliosis: a systematic review

    2020, Clinical Microbiology and Infection
    Citation Excerpt :

    Four studies were finally retained: two meta-analyses [40,41], one retrospective controlled study [42] and one prospective uncontrolled study [43]. QUADAS-2 quality assessment demonstrated low risk of bias and low applicability concerns for both meta-analyses [40,41], unclear risk of bias and uncertainty regarding applicability for the retrospective controlled study [42], and high risk of bias and high concerns regarding applicability for the prospective uncontrolled study [43]. As demonstrated previously for Lyme neuroborreliosis, the CSF CXCL-13 concentration is high [40–44].

  • Lyme borreliosis in children

    2022, Cesko-Slovenska Pediatrie
View all citing articles on Scopus
View full text